We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+9.54%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$109B
AUM Growth
+$10.1B
Cap. Flow
+$2.06B
Cap. Flow %
1.89%
Top 10 Hldgs %
23.41%
Holding
4,156
New
227
Increased
1,649
Reduced
1,885
Closed
242

Sector Composition

Rank Sector Weight
1 Technology 12.51%
2 Healthcare 9.35%
3 Financials 9.21%
4 Industrials 6.82%
5 Consumer Discretionary 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HPE icon
901
Hewlett Packard
HPE
$72B
$11.9M 0.01%
746,113
-457,966
-38% -$6.75M
IYR icon
902
iShares US Real Estate ETF
IYR
$4.48B
$11.9M 0.01%
141,276
+30,936
+28% +$2.6M
ALK icon
903
Alaska Air
ALK
$5.4B
$11.9M 0.01%
276,973
-9,735
-3% -$429K
MTCH icon
904
Match Group
MTCH
$8.45B
$11.9M 0.01%
286,298
-27,019
-9% -$1.22M
RWO icon
905
State Street SPDR Dow Jones Global Real Estate ETF
RWO
$1.27B
$11.8M 0.01%
288,688
+25,390
+10% +$1.03M
GEN icon
906
Gen Digital
GEN
$17.4B
$11.8M 0.01%
550,376
-96,329
-15% -$2.13M
GLDM icon
907
SPDR Gold MiniShares Trust
GLDM
$29.9B
$11.8M 0.01%
325,785
-27,968
-8% -$961K
TPR icon
908
Tapestry
TPR
$32.4B
$11.8M 0.01%
308,884
+54,748
+22% +$1.88M
HLNE icon
909
Hamilton Lane
HLNE
$5.78B
$11.7M 0.01%
183,889
-707
-0.4% -$47K
BIO icon
910
Bio-Rad Laboratories Class A
BIO
$9.53B
$11.7M 0.01%
27,900
+3,278
+13% +$1.32M
IEX icon
911
IDEX
IEX
$17.5B
$11.7M 0.01%
51,120
-2,097
-4% -$469K
ENSG icon
912
The Ensign Group
ENSG
$10.5B
$11.6M 0.01%
123,132
+11,561
+10% +$1.05M
VDC icon
913
Vanguard Consumer Staples ETF
VDC
$7.92B
$11.6M 0.01%
60,766
+6,422
+12% +$1.21M
MEDP icon
914
Medpace
MEDP
$16.9B
$11.6M 0.01%
54,534
-25,888
-32% -$5.17M
IOO icon
915
iShares Global 100 ETF
IOO
$9.41B
$11.6M 0.01%
180,762
+4,557
+3% +$292K
RPG icon
916
Invesco S&P 500 Pure Growth ETF
RPG
$2.04B
$11.5M 0.01%
380,550
-38,265
-9% -$1.18M
UTHR icon
917
United Therapeutics
UTHR
$22.1B
$11.5M 0.01%
41,462
-982
-2% -$248K
WTRG icon
918
Essential Utilities
WTRG
$11.4B
$11.5M 0.01%
241,197
-2,450
-1% -$111K
ARCC icon
919
Ares Capital
ARCC
$14.3B
$11.4M 0.01%
619,829
+32,764
+6% +$615K
SFBS
920
ServisFirst Bancshares
SFBS
$4.88B
$11.4M 0.01%
166,093
+3,276
+2% +$245K
HXL icon
921
Hexcel
HXL
$7.6B
$11.4M 0.01%
194,447
-454
-0.2% -$26K
NXST icon
922
Nexstar Media Group
NXST
$5.69B
$11.4M 0.01%
65,309
+22,366
+52% +$3.93M
AEL
923
DELISTED
American Equity Investment Life Holding Company
AEL
$11.4M 0.01%
250,559
-78,898
-24% -$3.18M
SBSW icon
924
Sibanye-Stillwater
SBSW
$7.51B
$11.4M 0.01%
1,068,728
+4,972
+0.5% +$50.5K
STLD icon
925
Steel Dynamics
STLD
$37.8B
$11.4M 0.01%
116,440
-26,390
-18% -$2.54M

Similar funds

Raymond James & Associates's Q4 2022 Portfolio in Review

As of Q4 2022, Raymond James & Associates held 4,156 positions worth $109B, up 10% from $98.8B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Raymond James & Associates's Q4 2022 filing shows 227 new, 1,649 increased, 1,885 reduced and 242 closed positions. Its largest new stake was Rentokil: 285,133 shares worth $8.78M. The largest sale was iShares Expanded Tech Sector ETF, an estimated $79.2M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q4 2022 buy was Rentokil: 285,133 shares worth $8.78M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q4 2022, an estimated $169M increase.
  • Raymond James & Associates's biggest Q4 2022 reduction was iShares Expanded Tech Sector ETF, cutting an estimated $79.2M.
  • Raymond James & Associates fully exited Change Healthcare Inc. Common Stock in Q4 2022, selling an estimated $53.3M.
  • Raymond James & Associates's ten largest holdings make up 23% of its $109B portfolio in Q4 2022.
  • Raymond James & Associates opened 227 new positions and closed 242 in Q4 2022.
  • Raymond James & Associates's portfolio value rose 10% quarter-over-quarter to $109B.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.